BioSight
Companies
Alkermes plc. logo

ALKS

NASDAQDUBLIN 4, L2
Alkermes plc.

Alkermes plc is a commercial-stage biopharmaceutical company with approved products including LUMRYZ, a small molecule treatment in psychiatry that is subject to a Risk Evaluation and Mitigation Strategy program. The company generates revenues from product sales and manufacturing or royalty revenues from licensed products, and operates in the psychiatry and related therapeutic areas with a commercial-stage portfolio focused on CNS conditions.

Price history not yet available for ALKS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar